4//SEC Filing
FORSYTH DOUGLAS 4
Accession 0000950142-24-001491
CIK 0002007919other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:10 PM ET
Size
8.5 KB
Accession
0000950142-24-001491
Insider Transaction Report
Form 4
FORSYTH DOUGLAS
Director
Transactions
- Award
Common Stock
2024-05-29+149,564→ 149,564 total(indirect: By Trust) - Award
Stock Option (right to buy)
2024-05-30+30,000→ 30,000 totalExercise: $15.86Exp: 2034-05-30→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.
- [F2]The reporting person is a trustee of the Forsyth Family Trust Dated July 20, 2001 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Forsyth Family Trust Dated July 20, 2001.
- [F3]This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
- [F4]This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date.
Documents
Issuer
Inhibrx Biosciences, Inc.
CIK 0002007919
Entity typeother
Related Parties
1- filerCIK 0001240801
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:10 PM ET
- Size
- 8.5 KB